Home  > News

Award-winning Science with Outstanding Commercial Potential in Cardiovascular Disease

1 July 2015, Munich, Germany -- Ascenion’s partner, Prof. Thomas Thum from the Hannover Medical School (MHH), today receives the prestigious Outstanding Investigator Award from the International Society of Heart Research (ISHR). ISHR honours Prof. Thum for his exceptional contributions to the advance­ment of cardiovascular science. In landmark studies, he demonstrated the potential of regulatory RNA molecules for the diagnosis and treatment of heart diseases.

Together with Ascenion, the MHH’s technology transfer partner, he is pioneering the translation of these results into medical applications. ‘Heart insufficiency is a result of a pathological process,’ Prof. Thum explains. In various in-vivo models of cardiac disease, his team was able to show that this process can be stopped and even reversed by the specific inhibition certain microRNAs and lncRNAs. ‘It is the target, which makes all the difference,’ he says. ‘To my knowledge, there is currently no other approach under development with comparable capacity to heal the heart following infarction and to prevent cardiac failure.’

‘We congratulate Thomas and are celebrating this prestigious award with him,’ says Gregor Lichtfuss, Technology Manager with Ascenion. ‘His work on regulatory RNAs holds tremendous potential for millions of patients and we are delighted to be supporting the transfer of his impressive results into application.’

The growing awareness of regulatory RNAs, together with positive results from first clinical studies in other indications, drives an increasing demand in industry. Ascenion has already mediated first deals relating to IP resulting from Prof. Thum’s work and has created a set of further high-potential opportunities:

  • Therapeutic microRNAs and long non-coding RNAs with proven in-vivo efficacy in heart failure and post myocardial infarction healing READ MORE
  • Diagnostic biomarkers based on circulating miRNAs and lncRNAs that enable patient stratification and the early diagnosis of Takotsubo, myocardial infarction, acute kidney injury and multiple sclerosis READ MORE
  • Cardior Pharmaceuticals, a start-up in the process of being founded by Prof. Thum developing innovative treatments for heart failure, is currently seeking seed investors READ MORE


###

Contacts
For Ascenion

Communication:
Dr Susanne Letzelter
T: +49 89 318814-16
E: letzelter(at)ascenion(dot)de  

###

About Ascenion

Ascenion GmbH is an IP asset management company with particular expertise in the life sciences. Ascenion advises and supports public research institutions with regard to the protection and exploitation of their intellectual property (patents, know-how, materials), and initiates and mediates agreements between research institutions and industry. The company places particular emphasis on coaching company founders and on active equity management. Ascenion was founded in 2001 as a 100% subsidiary of the LifeScience Foundation for the Promotion of Science and Research and is technology transfer partner of 23 research institutes in the Helmholtz and Leibniz Associations, as well as of the Charité, the Hannover Medical School and the research institute TWINCORE. Ascenion currently markets around 750 technologies on behalf of these institutes, and closes an average of about 80 revenue-generating agreements between research and industry per year. The team has also coached numerous spin-offs through their foundation and early growth and Ascenion holds equity in 26 of these companies. Ascenion’s headquarters are in Munich, with further offices in Berlin, Braunschweig, Hamburg, Hanover and Neuherberg.
Further information at www.ascenion.de